Category Archives: Uncategorized

DEA Moves to Temporarily Schedule 7-Hydroxymitragynine (7-OH) and Related Substances

The U.S. Drug Enforcement Administration (DEA) has issued two Notices of Intent to temporarily place 7-hydroxymitragynine (7-OH) and three related substances into Schedule I of the Controlled Substances Act (CSA). This temporary scheduling includes: 7-Hydroxymitragynine (7-OH), Mitragynine pseudoindoxyl (MP), Dihydro-7-hydroxymitragynine (MGM-15), and 9-fluoro derivative of 7-hydroxymitragynine (MGM-16). These substances exhibit psychoactive, opioid-like effects, have unpredictable…
Read more

Radical Harm Reduction Policies Worsening the Opioid Crisis

Rather than investing in prevention strategies and expanding access to treatment and recovery services, British Columbia, Canada, chose to enact radical harm reduction policies—policies that are now being linked to a significant worsening of the opioid crisis. In March 2020, British Columbia launched its safer opioid supply policy, allowing physicians and nurse practitioners to prescribe…
Read more